Business Description
Sartorius Stedim Biotech SA
NAICS : 334510
SIC : 3844
ISIN : FR0013154002
Compare
Compare
Traded in other countries / regions
DIM.France0RG8.UKSRTOY.USA56S1.GermanyDIM.AustriaDIM.Mexico IPO Date
1994-10-20Description
Sartorius Stedim Biotech is a leading provider of tools for biopharmaceutical fermentation and fluid management. Parent Sartorius AG has a 74% stake in the company, with 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (38% of 2022 sales), the Americas (36%), and Asia-Pacific (26%). Sartorius Stedim Biotech employs over 10,000 people and has operations in more than 20 countries.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.08 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.53 | |||||
| Debt-to-EBITDA | 1.28 | |||||
| Interest Coverage | 19.1 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 6.86 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 34.3 | |||||
| 3-Year EBITDA Growth Rate | 49.9 | |||||
| 3-Year EPS without NRI Growth Rate | 55.3 | |||||
| 3-Year FCF Growth Rate | 1.4 | |||||
| 3-Year Book Growth Rate | 28.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 8.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 3.58 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.66 | |||||
| 9-Day RSI | 27.45 | |||||
| 14-Day RSI | 32.74 | |||||
| 6-1 Month Momentum % | -18.45 | |||||
| 12-1 Month Momentum % | -19.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.75 | |||||
| Quick Ratio | 0.63 | |||||
| Cash Ratio | 0.12 | |||||
| Days Inventory | 244.24 | |||||
| Days Sales Outstanding | 44.9 | |||||
| Days Payable | 103.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.63 | |||||
| Dividend Payout Ratio | 0.21 | |||||
| 3-Year Dividend Growth Rate | 30.3 | |||||
| Forward Dividend Yield % | 0.63 | |||||
| 5-Year Yield-on-Cost % | 1.49 | |||||
| Shareholder Yield % | -2.11 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.53 | |||||
| Operating Margin % | 26.21 | |||||
| Net Margin % | 20.04 | |||||
| ROE % | 27.01 | |||||
| ROA % | 12.8 | |||||
| ROIC % | 15.58 | |||||
| ROC (Joel Greenblatt) % | 47.58 | |||||
| ROCE % | 22.22 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 33.3 | |||||
| Forward PE Ratio | 32.68 | |||||
| PE Ratio without NRI | 33.3 | |||||
| Shiller PE Ratio | 65.15 | |||||
| Price-to-Owner-Earnings | 40 | |||||
| PEG Ratio | 0.93 | |||||
| PS Ratio | 6.68 | |||||
| PB Ratio | 8.24 | |||||
| Price-to-Tangible-Book | 39.24 | |||||
| Price-to-Free-Cash-Flow | 130.64 | |||||
| Price-to-Operating-Cash-Flow | 31.38 | |||||
| EV-to-EBIT | 26.07 | |||||
| EV-to-Forward-EBIT | 22.71 | |||||
| EV-to-EBITDA | 21.21 | |||||
| EV-to-Forward-EBITDA | 19.48 | |||||
| EV-to-Revenue | 7.07 | |||||
| EV-to-Forward-Revenue | 6.41 | |||||
| EV-to-FCF | 138.45 | |||||
| Price-to-Projected-FCF | 4.56 | |||||
| Price-to-DCF (Earnings Based) | 1.07 | |||||
| Price-to-DCF (FCF Based) | 4.18 | |||||
| Price-to-Median-PS-Value | 0.5 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.34 | |||||
| Price-to-Graham-Number | 7.63 | |||||
| Earnings Yield (Greenblatt) % | 3.84 | |||||
| Forward Rate of Return (Yacktman) % | 20.97 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sartorius Stedim Biotech SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3,170.2 | ||
| EPS (TTM) (€) | 6.9 | ||
| Beta | 0.35 | ||
| Volatility % | 35.71 | ||
| 14-Day RSI | 32.74 | ||
| 14-Day ATR (€) | 7.751454 | ||
| 20-Day SMA (€) | 252.825 | ||
| 12-1 Month Momentum % | -19.77 | ||
| 52-Week Range (€) | 211.5 - 363.8 | ||
| Shares Outstanding (Mil) | 92.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sartorius Stedim Biotech SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sartorius Stedim Biotech SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sartorius Stedim Biotech SA Frequently Asked Questions
What is Sartorius Stedim Biotech SA(XPAR:DIM)'s stock price today?
The current price of XPAR:DIM is €229.80. The 52 week high of XPAR:DIM is €363.80 and 52 week low is €211.50.
When is next earnings date of Sartorius Stedim Biotech SA(XPAR:DIM)?
The next earnings date of Sartorius Stedim Biotech SA(XPAR:DIM) is 2023-10-19.
Does Sartorius Stedim Biotech SA(XPAR:DIM) pay dividends? If so, how much?
The Dividend Yield %  of Sartorius Stedim Biotech SA(XPAR:DIM) is 0.63% (As of Today), Highest Dividend Payout Ratio of Sartorius Stedim Biotech SA(XPAR:DIM) was 0.26. The lowest was 0.09. And the median was 0.2. The  Forward Dividend Yield % of Sartorius Stedim Biotech SA(XPAR:DIM) is 0.63%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers